Plasma apolipoprotein e and Alzheimer disease risk: The AIBL study of aging

Neurology

Volumn 76, Issue 12, 2011, Pages 1091-1098

  Gupta, V B ^a,b   Laws, S M ^a,b   Villemagne, V L ^c,d   Ames, D ^d,e   Bush, A I ^d   Ellis, K A ^d,e   Lui, J K ^a,b   Masters, C ^d   Rowe, C C ^c   Szoeke, C ^e,f   Taddei, K ^a,b   Martins, R N ^a,b  

^a EDITH COWAN UNIVERSITY   (Australia)

^b Hollywood Private Hospital   (United States)

^c AUSTIN HEALTH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^f CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PITTSBURGH COMPOUND B; TRIACYLGLYCEROL;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGED; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; BRAIN; CARBON RADIOISOTOPES; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; HETEROZYGOTE; HOMOZYGOTE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RISK FACTORS; THIAZOLES;

EID: 79953193799     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318211c352     Document Type: Article

References (31)

1. Salmon DP, Lange KL. Cognitive screening and neuropsychological assessment in early Alzheimer's disease. Clin Geriatr Med 2001;17:229-254. (Pubitemid 32429329)
2. Hesse C, Larsson H, Fredman P, et al. Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem Res 2000;25:511-517. (Pubitemid 30317684)
3. Lehtimaki T, Pirttila T, Mehta PD, et al. Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum Genet 1995;95:39-42.
4. Taddei K, Clarnette R, Gandy SE, Martins RN. Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. Neurosci Lett 1997;223:29-32. (Pubitemid 27093012)
5. Hahne S, Nordstedt C, Ahlin A, Nyback H. Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls. Neurosci Lett 1997; 224:99-102. (Pubitemid 27122180)
6. Laws SM, Hone E, Taddei K, et al. Variation at the APOE-491 promoter locus is associated with altered brain levels of apolipoprotein E. Mol Psychiatry 2002;7:886-890.
7. Laws SM, Taddei K, Martins G, et al. The-491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease. Neuroreport 1999;10:879-882. (Pubitemid 29393839)
8. Pirttila T, Koivisto K, Mehta PD, et al. Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease. Neurosci Lett 1998;249:21-24. (Pubitemid 28308224)
9. Siest G, Bertrand P, Qin B, et al. Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study: ApoEurope group. Clin Chem Lab Med 2000;38:721-730.
10. Slooter AJ, de Knijff P, Hofman A, et al. Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study. Neurosci Lett 1998;248:21-24. (Pubitemid 28267093)
11. Ellis KA, Bush AI, Darby D, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 2009;21:672-687.
12. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
13. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308. (Pubitemid 29120227)
14. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240-246. (Pubitemid 39222993)
15. Silbert BS, Evered LA, Scott DA, Cowie TF. The apolipoprotein E epsilon4 allele is not associated with cognitive dysfunction in cardiac surgery. Ann Thorac Surg 2008;86:841-847.
16. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007;130: 2837-2844. (Pubitemid 350033975)
17. Panza F, Solfrizzi V, Colacicco AM, et al. Apolipoprotein E (APOE) polymorphism influences serum APOE levels in Alzheimer's disease patients and centenarians. Neuroreport 2003;14:605-608. (Pubitemid 36528999)
18. Riddell DR, Zhou H, Atchison K, et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci 2008;28:11445-11453.
19. Roses AD. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease. Ann Neurol 1995;38:6-14.
20. St George-Hyslop P, McLachlan DC, Tsuda T, et al. Alzheimer's disease and possible gene interaction. Science 1994;263:537. (Pubitemid 24082757)
21. Fukumoto H, Ingelsson M, Garevik N, et al. APOE epsilon 3/epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis. Exp Neurol 2003;183:249-253. (Pubitemid 37075875)
22. Huang Y, Liu XQ, Wyss-Coray T, et al. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci USA 2001;98:8838-8843. (Pubitemid 32678114)
23. Gregg RE, Zech LA, Schaefer EJ, et al. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest 1986;78:815-821. (Pubitemid 16024820)
24. Morrow JA, Hatters DM, Lu B, et al. Apolipoprotein E4 forms a molten globule: a potential basis for its association with disease. J Biol Chem 2002;277:50380-50385. (Pubitemid 36042188)
25. Pfrieger FW. Role of cholesterol in synapse formation and function. Biochim Biophys Acta 2003;1610:271-280. (Pubitemid 36324470)
26. Stratman NC, Castle CK, Taylor BM, et al. Isoform-specific interactions of human apolipoprotein E to an intermediate conformation of human Alzheimer amyloid-beta peptide. Chem Phys Lipids 2005;137:52-61. (Pubitemid 41405832)
27. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43:1467-1472. (Pubitemid 23230526)
28. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90: 1977-1981. (Pubitemid 23069980)
29. Rebeck GW, Reiter JS, Strickland DK, et al. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993;11:575-580. (Pubitemid 23321768)
30. Beffert U, Cohn JS, Petit-Turcotte C, et al. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are diseaserelated and apolipoprotein E genotype dependent. Brain Res 1999;843:87-94. (Pubitemid 29488698)
31. Ramaswamy G, Xu Q, Huang Y, Weisgraber KH. Effect of domain interaction on apolipoprotein E levels in mouse brain. J Neurosci 2005;25:10658-10663. (Pubitemid 41681913)